Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What benefit will Taran get from the recall of the loaned shares?
Taran holds the IP rights, and Humanigen is likely holding ~90% of all the shares the company issued, with a float of 192% of the OS.
Let's just see how the reorganization develops. Humanigen is sure to maintain majority control, if necessary.
In May of 2021, #DR. PETER MCCULLOUGH, who testified about a lack of covid treatment options in front of both the national, as well as the Texas legisative oversight committees, questioned why there were no defined covid treatment protocols established. He specifically questioned where guidance was offered by The Mayo Clinic.
see the discussion from minute marks 14:30 - 15:30.
https://www.bitchute.com/video/gDXcWb4tgAkj/
I can assure Dr. McCullough that Mayo clinical trial investigators were fully engaged in the effort to bring a safe and effective covid therapeutic to market. Several of their trial investigators, working with Humanigen, led a Phase III trial of Humanigen's Lenzilumab, concluding with tremendous success (HR 1.54).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635458/
I think that #Dr. John Campbell, an English doctor I greatly admire for his fact-based research and reporting, would be even more impressed with Humanigen's reporting of outcomes based on CRP levels, which Humanigen established as a biomarker. Those results were peer-reviewed by Thorax, as shown on page 5.
"Effect of CRP<150 mg/L on SWOV and secondary endpoints in
LIVE-AIR
In participants with baseline CRP <150 mg/L, lenzilumab
improved the likelihood of SWOV compared with placebo
(HR: 2.54; 95% CI 1.46 to 4.41; nominal p=0.0009;"
https://thorax.bmj.com/content/thoraxjnl/early/2022/07/05/thoraxjnl-2022-218744.full.pdf
Humanigen's home page reflects this information, as well as the peer-review by Lancet.
https://www.humanigen.com/
Additional review established Hazard Ratios of between 3.0 - 3.4.
It has been my belief that the FDA's refusal to authorize lenzilumab (lenz) amounted to willful negligence, if not criminal negligence. Mr. Andrew Bridgen, MP, went even further. I ask #Texas Attorney General Ken Paxton to consider Mr. Bridgen's letter to Scotland yard in this regard. Texas Medicaid funds should not be used for mRNA vaccines that are resulting in more excess deaths in one year, than the number of soldiers killed in all American wars combined.
https://twitter.com/ABridgen/status/1765069935603306651/photo/1
There remains the indication for which lenzilumab was intended, and in which it has demonstrated tremendous promise. And I hope that lenz will be very successful in treating cancers, such as CMML.
But there remains two realities. First is, that the world has no safe and effective covid preventative. And secondly, there is no variant-agnostic therapeutic for covid, let alone one that could imbue an appropriate immune response against future infections.
The fact that excess deaths are attributed to mRNA vaccines, WHICH ARE STILL BEING ADMINISTERED AND ENCOURAGED, is another reason that the Novavax vaccine, in it's best form, has to be brought to market, with it's lenz enhancement. In less than a year, excess deaths from mRNA vaccines have cost more lives than all the soldiers lost in all the battles, combined, in the US.
And we are welcoming illegal immigrants by the tens of thousands, even though their countrymen have already been discovered operating biotechs on our soil, designed to spread covid and a variety of lethal diseases across our land.
The tracks on which the train has left don't just run one way. And at the least, we need to be prepared for when the train returns.
I think management is working on the application of their lenz/vaccine/anti-viral patented process. Novavax is the only US-based covid vaccine manufacturer with a traditional vaccine, which I think would be compatible for use with lenz as an enhancement.
If Humanigen has about $4M worth of lenz in-process of being manufactured, that might be enough for a re-formulated version of lenz to be administered either orally or subcutaneously, along with millions, even tens of millions, of Nuvaxovid vaccines.
I can only tell you what I think management may be working on. This is it, in large part.
Novavax issues a second set of stock options in two weeks.
https://www.sec.gov/cgi-bin/browse-edgar?company=novavax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
On March 11th, Novavax issued the following Press Release (which I didn't see highlighted by the FDA's site).
https://ir.novavax.com/press-releases/Canada-National-Advisory-Committee-Publishes-Recommendation-for-Use-of-Novavaxs-Nuvaxovid-TM-XBB-1-5-COVID-19-Vaccine
https://newsfilter.io/
Regarding "Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)."
"Early reports from studies with patients with long COVID suggests a constellation of symptoms with similarities to another chronic medical illness-myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). A review study comparing and contrasting ME/CFS with reported symptoms of long COVID may yield mutualistic insight into the characterization and management of both conditions."
https://pubmed.ncbi.nlm.nih.gov/33925784/
I listened to an interview of Dr. Pierre Kory, who discussed Long Covid (which he says is mainly Long Vax), and says that what we're calling Long Covid is the same, or about the same, as ME/CSF, and he mentioned that Epstein-Barr was another similar indication. And I got to thinking about lenzilumab being considered for this, at one point. But more specifically, I wondered HOW lenz may be effective in treatment of this indication. Despite the similarities of Long Covid to mono, how would lenz improve CFS in patients with HLA from mono?
But he also said something of more importance to Humanigen and the shareholders. As we noted in real time, both Lancet and Thorax took exceptionally long times to complete the publications of their peer reviews, even though the results of both were stellar. Dr. Kori also noted issues regarding the medical journals, and went so far as to state his opinion that this is now where the degradation of the medical field starts. Further, he went on to say that RFK, Jr., said that he would summon the chief editors of the medical journals into his office, if elected, and file RICO charges against them, if they didn't restore integrity to their publications.
So, I think this could be further evidence of management's conviction, and lenzilumab's safety and efficacy, if Dr. Kori is right. Management may have had to fight to get fair and honest assessments of lenzilumab's performance. Something caused the extremely lengthy review times, and lenz is a profit killer for Pfizer and Moderna.
I had earlier reported an interview of Steve Kirsch, whose study revealed that autism is totally caused by vaccines, and has been, for years.
What these doctors are saying is important.
However, Tucker conducted both interviews. I think it's irrelevant to the information being conveyed by the doctors. But in this post, I included an NIH corroborative study to help focus on the subject.
I'd like to think that macro-level medical considerations do not have a hand in what transpires here. But as I look forward to a pathway of consensus regarding mRNA vaccines, I also anticipate that a new division will develop in regards to the WHO's role in dictating how our healthcare system functions in the United States. So things may get worse before they get better, if they are able to get better. I'm not optimistic. I don't trust our own federal government to represent our interest, and I suspect a WHO-directed role in the US and world-wide will have an unfortunate amount of support from the British and American public. Objectivity could become further constrained, especially on a small biotech message board.
Let's hope for the best, Brother! For the medical community to awaken to the value of lenz as a traditional vaccine-enhancement, as well as a therapeutic, will be a good thing!
AstraZeneca vaccine victims win court decision for damages, brought on violation of the Consumer Protection Act, and negating AZ's impunity. Will other vaccine manufacturers likewise face damages?
Actually, I have begun 'ignoring' this guy (or these guys) when I see them arrive with a brand new nickname, and an agenda. I see the material on stocktwits, and I gain nothing by seeing it again here. Historically, I never had any poster on ignore, despite so many people advising me to ignore this poster, or that one, over the years. But, Ihub offers the 'ignore' function, and for these virgin antagonists, I use the option to ignore them. There are other, more important issues to focus on.
Actually, Chaplain, I haven't deleted any of the posts, lately, many of which were mine. DTG hasn't, either.
If there is a problem, then there is also a reason for the problem.
And any such problem is beyond my authority to fix. I've tried, to the extent that I can. The present situation is unfortunate, and I hope we can return to the fairly good order we had.
Yes, I am saying that we can resubmit the EUA, and obtain a favorable decision, with the data, as written. Adding additional data from the ACTIV-5 patients in ordinal scale 5, and adding the PREACH-M trial results, would just be window dressing, and allow some face-saving for the FDA.
Our LIVE-AIR trial data was sufficient in volume, and exemplary in result. The trial results stand on their own. That fact is irrefutable, and I stand by that conclusion.
Thousands of people are still suffering preventable deaths from covid every week. So to me, there is nothing comical about the facts.
Doctors, independently, know how corrupt the FDA is, and they don't speak out. But I think they will, when the WHO starts dictating how they are to run their practices, and treat their patients. I don't know how woke the AMA is, but I hope they will be forced by their membership to defend their medical sovereignty.
The data from the LIVE-AIR patient population would be of sufficient volume for the FDA to make a regulatory decision. Trial size was established in consultation between the FDA and management.
The NIH ACTIV-5 trial tested late stage patients, including patients who had, or were on, IMV. The FDA even included patients on ECMO, whose outcomes were not to be factored into the trial results.
No new trial is required for an EUA. We should be able to extract ACTIV-5 results for their patients who were in ordinal scale 5, and use those results as an adjunct to the LIVE-AIR trial results, if necessary. The ACTIV-5 patients in ordinal scales 6 and 7 were too progressed in disease severity, and were not included in LIVE-AIR. We also have safety and efficacy data from lenz on the PREACH-M study, which may soon win approval in Australia, and all of this data could be included in a resubmission of our EUA application. I think our OS is already higher than management wants, and I doubt they will reverse split, even at 1:5. There will be no need to do so, anyway, after the loaned shares are recalled, and we could even see a forward split, which I hope we don't, even f it would be temporary.
Welcome to the room, SorcererGuru44, and thank you for your considerate post.
Good news for Invivyd (IVVD), and signals Regulatory stance on mAbs.
"March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc...today announced interim exploratory COVID-19 clinical event data for VYD222, an investigational, monoclonal antibody (mAb) in development for the pre-exposure prophylaxis of COVID-19."
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-interim-exploratory-data-vyd222-ongoing-canopy
Invivyd is defining 'pre-exposure' differently than I am accustomed to seeing. They are not saying their mAb is for covid-naive patients. They're saying just the opposite.
"Exploratory data such as provided in today’s update are important for broad reflection as they represent some of the first data from a clinical trial conducted with a monoclonal antibody in a population that has acquired prior immune exposure from either vaccination or natural infection. By contrast, studies of prior authorized COVID-19 PrEP mAbs largely relied on participants required by protocol to be naïve to vaccination or prior infection." I guess the mass vaccination assault expanded the allowable definition of 'pre-exposure prophylaxis.'
In addition to the above Release Details, Invivyd also issued Release Details, which mentions the EUA.
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-fda-authorization-emergency-use-pemgardatm
I'm actually encouraged by this.
"A PREP Act declaration is specifically for the purpose of providing immunity from liability"
https://aspr.hhs.gov/legal/PREPact/Pages/default.aspx
It only makes sense to have an alternative, traditional vaccine, available to meet healthcare demands, in the event that mRNA vaccine manufacturers withdraw from the market, when PREP Act protection expires. The only traditional vaccine approved for use in the US is the Novavax vaccine. If the safety and efficacy of that vaccine proves to be enhanced by Humanigen's patented methodology, using lenzilumab, then the company needs to be prepared to meet that demand.
Not only is the subject germane, the issue is critical. We cannot let a highly lethal virus attach to receptor cells, and if they do, we need to combat the effects of that infection vigorously and effectively, using lenzilumab, in both processes. Lenzilumab showed outstanding results when administered early. The LIVE-AIR trial met the primary endpoint, and those results have been peer-reviewed by both Lancet and Thorax. The company has a history of treatment data for the product, even preceding Covid.
You could be absolutely right, dlog.
Because I believe in the huge potential of lenz to effectively treat, and then to possibly prevent, a huge number of indications, and also because I believe in the good character of our management, I have made it my objective to try to understand what this management team is doing to get their lenz into the market. And I have shared my conclusions and opinions here.
Yes, there would have been benefit with an earlier recall of the loaned shares. It would have amounted to a blip on the radar. Even if it staved off the bankruptcy, the momentum would not have been sustained, without news leading to our ability to generate a revenue stream.
In the US, and in the UK, we're looking for regulatory approval for lenz to treat covid. That would cause the FDA and the MHRA to destroy the markets for Pfizer and Moderna, who provide the vast majority of the regulators' operating funds. It would also threaten the value of the intellectual property OWNED BY THE REGULATORS in the Pfizer and Moderna mRNA vaccines. Regulators would be slicing their own financial throats by approving Humanigen's lenzilumab, and the Novavax vaccine that uses lenz as an enhancement.
We have to capitalize on the IND authorization by having partners use lenz under IND for their vaccine and CAR-T products. We also need to exploit our opportunity for regulatory approval of lenz from Australia, to treat CMML. It's almost "game-over" for the attempts to deny our revenue stream. We will prevail. It would be an absolute catastrophe to use mRNA technology to fight a virus that could have 100% mortality, such as the Pangolin Coronavirus.
We need to see regulatory approval of lenz, which is most likely to first come from Australia. And the flood gates will then be open.
And that's when management can recall their loaned shares to the fullest monetary advantage.
I think Shkreli executed the recall of the loaned shares to re-pay his hedge fund clients from the short squeeze proceeds. Regardless of whether I over-estimated his character, or not, our short squeeze proceeds will go to funding our operational requirements, and likely regain compliance with OTC requirements for quotation, before moving back to Nasdaq.
Novavax's financial condition can do a complete reversal, if their prototype vaccine incorporated a lenz enhancement.
Anyway, once the pieces are in place, then will be the time to evaluate what "...cam has shown..."
My tenacity is just a reflection of my conviction in the character of our management, and in the safety and efficacy of lenz, which is poised to be enthusiastically embraced by the medical community, for a whole host of indications. We've never been stronger, but we will be.
You and I both posted here initially in 2015, so your opinion of me is based on a pretty complete awareness of my conclusions. I may have been able to make a more complete case, for instance, in regards to the share recall, perhaps if those records weren't sealed, and if we saw the charges against Dale's entities. The SEC didn't waste any time after the Kalobios squeeze, and charges against Dale's entities go all the way back to the very time that we became Humanigen. Still, I think Dale very likely won his Appeal. The share structure was managed meticulously, and I believe we will see a float of ~229M shares, which will cause a monster short squeeze when the loaned shares are recalled.
You are correct in saying that an opportunity with Novavax exists only in my head. There's been no sign of it otherwise. But they are the prime candidate that would qualify to use our lenz/vaccine patent, and I think they will have that opportunity as the deadly mRNA vaccines are losing market share, even before the Humanigen/Novavax product comes to market.
Hopefully, we have a pretty decent revenue stream from Gracell, and also hopefully we will be able to snag Tera-Immune, especially if Sanofi expands our opportunity to use the Treg process. Sanofi has always had a complimentary product line to Humanigen, and I look forward to the spin-off of their healthcare business. Don't discount that potential. They were here even before we showed up in 2015.
"I don't think there is any way in hell that Pfizer and Moderna will stay in the covid vaccine market past the end of the year, and run the risk of putting their mRNA vaccines into the market, without immunity from prosecution."
We'll see if that proves to be the case. It would definitely mean admitting defeat on the course that Pfizer, Moderna, and the FDA have been mandating.
And in the UK, I see what could be further recognition that the wrong covid treatment course was chosen. The UK announced that the fourth module of their national Covid-19 Inquiry will be rescheduled.
start at the beginning. this section of information concludes at the 4 minute mark, and goes on to an important discussion of 'Disease X.'
Tell it to the bankruptcy court judge. He obviously saw no cause to convert the case to CH7, which he should have done, if you guys are right about how worthless we are.
But you're right about the reaction we should have gotten from the clinical trials. The reaction we got from the Top Line Data should have indicated what to expect from the FDA decision.
The powers that be are losing control. Patients and doctors are not buying the mRNA vaccines as they were. It's time for lenz.
The $10K was the company's stated price for the therapeutic infusions.
I wondered about the cost of lenz, if used as a vaccine enhancement. Dosage and formulation of lenz for that application may be substantially less.
The vascular surgeon did two atherectomies in a procedure last year, leaving me with a long stent. I was supposed to have a follow-up visit with him last week, which was contingent on how much that was going to cost. The doctor's staff told me last week how much the insurance wouldn't pay, and I rescheduled the appointment. And yes, for the first time in my life, I began taking a few prescription drugs last year, as you surmised.
I hate to leave the house, but I have always hated leaving the house. It's just that this time, I drag my feet getting ready, until I finally succeed in becoming too late to go anywhere.
DTG, I don't interpret Durrant's comments as you do. I think the key is in what was not said. It does not consider the reasons why the bankruptcy court judge is discharging the case as a CH11. I'm glad that you recognize the potential of a looming recall of the loaned shares. But the magnitude of that impact, when it comes, will be far from some pittance for the poor Humanigen shareholders.
I'm not discounting the reasonableness of anyone who comes to that deduction. In fact, I recognize that my own estimation of the value of lenz in treating covid needs more than just an appreciation of the safety and efficacy of the product. The value I attach to lenz for covid requires a degree of necessity that that value comes to light. Now, that necessity is becoming exposed, by the deadly health effects of the mRNA vaccines. The medical community needs to see that lenz has a role in helping to prevent covid pneumonia infection, without contributing to excess deaths overall. They need to see that lenz is the best therapeutic capable of safely curing the infection, and that lenz can prevent future reoccurrences of covid.
I think the stage is set to showcase lenzilumab's role in fighting covid, both as a prophylaxis, and as a therapeutic. And I think Novavax may become the partner we need to establish control of the worldwide covid market. I think those steps must be taken, for the protection of the populace. And I believe those steps are being taken.
It's been a year since Humanigen filed a 10-Q, which indicated a cash balance of about $3.1M.
pg 4
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923007002/hgen-20230331.htm
The bankruptcy filing claimed a cash balance of only about $500K.
https://www.reuters.com/business/healthcare-pharmaceuticals/covid-19-treatment-developer-humanigen-files-chapter-11-bankruptcy-2024-01-04/#:~:text=Jan%204%20(Reuters)%20%2D%20Drug,for%20its%20COVID%2D19%20treatment.
And we know the bankruptcy judge had approved of Taran providing $1M in financing, ahead of the closing of the bankruptcy, when they paid an additional $1M.
So we could have about $4M of additional lenz either produced, or scheduled to be produced. Starting a revenue stream is a required objective for Humanigen/Taran, and with Durrant investing millions into the operation at this point, I don't see why I should be worried, if he isn't.
The frenemies who, along with the FDA, kept us out of the market, are themselves now financially threatened. People are waking up to the harm inflicted by the mRNA vaccines. That is resulting in substantial revenue declines for Pfizer and Moderna, and steep cuts in FDA funding operations from Big Pharma, including licensing fees required of Big Pharma to the FDA.
If we get Novavax to use lenz under the approved IND authorization, to enhance the efficacy their vaccine with our patented formulation, we will own the covid market. Investors will be clamoring to buy shares, and Humanigen owns ~90% of the Outstanding Shares. But prospective buyers will have to compete with brokerages who will be faced with a recall of the loaned shares.
And that is just looking at the covid scenario, which seems more likely than ever, and much larger than ever. We also know that CMML treatment approval looks likely in Australia.
Taran can do nothing to meet the demand for shares.
I don't see how anyone could say that Humanigen has nothing to do with lenz. How much of the product in the pipeline does Taran own?
"I definitely could have blended right in with those guys."
In fact, believe it or not, I love to sing in choirs, and some of 'John's Boys' heard some of my country covers, and wanted me to join the group. I declined, because they wanted to re-imagine the choir, and become the ChippenWales.
Well, I did say, believe it, or not.
I initiated this thread by focusing on lenzilumab's strong binding affinity and slow off-rate. I think Ivermectin can be a useful therapeutic against covid (it seems to actually bind the covid spike protein), instead of binding GM-CSF. But it seems that as soon as Ivermectin is ceased, all the symptoms patients were suffering come roaring back. It's just an issue I would like to know more about, if regulators continue to keep lenzilumab on the shelf.
Additionally, there is an issue regarding significantly reduced energy levels. That affects me, and I've got a couple acres of land I've got to maintain this spring. I thought it was my being lazy, progressing to just becoming lazier. But this is now ridiculous, and even somewhat debilitating. That's another reason I want to look into this subject. I had already practically self-diagnosed myself as having Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Symptoms can include problems thinking and concentrating, which I try to alleviate with staying engaged here (just don't make me read another 10-Q, or anything else from a bankruptcy court filing), and practically becoming house-bound (but I've always been a homebody).
Anyway, thank you for letting me know that Humanigen doesn't own the lenz IP. I don't anticipate that will adversely impact the safety and efficacy of lenz. Nor do I think it will result in one less short share being recalled. When that happens, I might even get to enjoy a curative dose of adrenaline!
Both Sanofi and Novavax have been tending to details regarding Beneficial Ownership Statements.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&owner=include&count=40&hidefilings=0
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001000694&owner=exclude
How does it benefit Taran to own the IP to a drug that has a strong binding affinity (25 pM) and a slow off-rate?
For further study:
"Lenzilumab is a novel Humaneered® anti-human GM-CSF monoclonal antibody that binds directly to the GM-CSF and blocks further signalling through its receptor. It also showed strong binding affinity (25 pM) and a slow off-rate
https://link.springer.com/article/10.1007/s10787-021-00903-x
Ivermectin, and it's binding of the spike protein
In my initial reply to your post, I failed to acknowledge the first clause in your question. The answer, despite my earlier language in an unrelated post, is that, yes, all is well with me.
However, someone I care about is having some health issues, and I wanted her to see the videos in a couple of my posts. She had told me that she has had some boosters, following a Pfizer vaccine. I have never had a post rejected on this site, AND blocked on X. But, there's a first time for everything. So I had to email the videos to her, and hope that she can open the videos from her email, or that she finds those videos in other of my postings here.
You also expressed some question about Humanigen's right to use lenz. And I see others here also concerned about our future.
For years, I have talked about the "script" written in our company's history. In 2015, as now, the company was forced into a CH11 bankruptcy, just as we were again forced to do. And too many shareholders are failing to continue looking to our past, to project our future. This wasn't The End of the company in 2015, and it isn't The End of the company now, either.
Shareholders need to realize that Humanigen remains on track toward accomplishing their goals. If there has been a change, I think we may see management rely more on foreign regulatory approval. Certainly, we are seeing the British parliament address issues such as excess deaths from mRNA vaccines. This has got to force the MHRA to abandon the status quo, and to consider granting approval of lenz to treat covid.
Other treatments could even capitalize on plant-based alternatives to controlling cytokine release syndrome.
https://www.nasdaq.com/press-release/gb-sciences-targets-covid-19-treatment-as-omicron-variant-arrives-2021-12-06
I think we may be in an ETF with them (but don't ask me to explain that). All I could do was to buy a small number shares in the company.
Finally, to me, there was an unknown distinction between SAR-S CoV-2 coronavirus in nucleocapsid proteins, caused by the virus, versus covid spike proteins caused by the mRNA vaccines. I really hope that a study has been done focused on the reduction of nucleocapsid covid proteins after administering lenz.
The only source I have for this observation is Bret Weinstein. I've hear him comment about the Chinese immigrants in various interviews, and you can hear what he tells Joe Rogan from the 4:05 minute mark.
MP Andrew Bridgen addresses British Parliament on the issue of excess deaths due to mRNA vaccines.
At the 7:30 minute mark, he quotes an expert opinion that the cause of these excess deaths has to be the experimental mRNA vaccines.
A lot of our presentations are no longer available, which is where I thought this was communicated. I'll keep looking. I've seen so many slides recently with covid spike proteins, and SARs-CoV2 nucleocapsid proteins, throughout the body, I may have mis-learned how those proteins get there.
It's very alarming that the Chinese illegal immigrants, who cross the border just as other foreign nationals are crossing the border, apparently segregate themselves while making the trek here, and seem to have their own camp sites on the trail, such as they have in San Vicente, in the Darien Gap. Non-Chinese are prohibited from even entering that camp site, and the Chinese do not communicate with the others. I haven't mentioned that earlier, because I only have a single source for that information. But my point is that I think this represents a serious threat of biological attack to our country. Yes, we have only found one (combined from two) illegal biotech labs being operated by Chinese nationals on our soil, and we only have two Chinese balloons (which can be equipped with biological dispersion capability) that have been observed in our airspace. But we also have illegal immigrants from the Middle East entering our country. The point is, that we cannot tolerate the lack of a true covid vaccine, or not having a safe and effective covid therapeutic that will also prevent rebound infections.
Covid will never be over. But lenz can prevent covid pneumonia infections in the future.
We have to assume that Humanigen has a license to use lenz, since Taran bought the IP...or, we just need to see the merger or business combination between Taran and Humanigen. I think that Humanigen has every intention to use lenz for covid, or Durrant would have simply bought out Humanigen.
Yes, I think that WAS the Big Pharma/Government objective, to keep us dependent on them.
But, too much evidence is surfacing that the mRNA vaccines (maybe even the adenovirus ones), are causing excess deaths. And I hope that Durrant is going to capitalize on the British Parliament's intent to put a stop to that, and the MHRA may finally approve lenz for covid.
Yes and no, ben. Durrant has gotten FDA approval of many drugs throughout his career, including several that proved to be blockbusters. So I think that demonstrates that he is actually an expert at knowing "what it takes to get a drug approved."
But that also means that regulators can't bullshit him. Yet, that is what they are trying to do. So Durrant knows what he has to do now.
The thing I like about Novavax is that they got regulatory approval from countries all around the world, before trying to get FDA approval in the US. The CEO they had was smart enough to do that, but fell short of managing operations afterwards. So they have a new CEO, and he seems better at managing operations. And I hope they end up partnering with Humanigen, and use lenz as a vaccine enhancement.
But we need lenz approved by a regulator, and I think the UK will finally be the regulator that approves lenz? Why? Because they have to.
My focus lately has been been on the UK's response to reality. I've been showing videos that graphically demonstrate that reality (for my reference, I'm talking about post numbers 42034 and 42035). Still, there is enough video evidence that I've been permitted to show that Humanigen's/Taran's lenz should be used in place of the mRNA vaccines. The proof is incontrovertible.
Not only are doctors/embalmers seeing novel presentations of the deadly blood clots they are finding post-mortem, actuaries and researchers are substantiating the physical evidence with statistical evidence. They are demonstrating multiple findings, such as significant excess deaths, in those patients who had mRNA vaccines.
In Durrant's post (which I still can't find) about Taran's objectives going forward, he didn't specifically mention covid. I hope, however, that's because Humanigen may continue that effort after they recall their loaned shares, and therefore have the funds to proceed.
This is what management did.
"Effect of CRP<150 mg/L on SWOV and secondary endpoints in
LIVE-AIR
In participants with baseline CRP <150 mg/L, lenzilumab
improved the likelihood of SWOV compared with placebo
(HR: 2.54; 95% CI 1.46 to 4.41; nominal p=0.0009; table 2a,
figure 2B). Separation of the survival curves appeared earlier
than in the overall population and followed a similar pattern
as the overall population thereafter (figure 2B). The number
needed to treat (NNT) was nine for this group compared with
17 for the overall population (table 2A). SWOV, in response to
lenzilumab treatment, was similar to placebo in participants with
CRP ≥150 mg/L at baseline (table 2A and figure 2C). The NNT
for this group was 37 (table 2A)"
https://thorax.bmj.com/content/thoraxjnl/early/2022/07/05/thoraxjnl-2022-218744.full.pdf
How can you look at those results, and NOT blame the FDA for withholding our EUA? That shows stellar performance of lenzilumab, captured brilliantly by the LIVE-AIR trial investigators.